Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
